BOS
TXG icon

Bingham Osborn & Scarborough’s 10x Genomics TXG Stock Holding History

Bingham Osborn & Scarborough’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,820
Closed -$227K – 167
2020
Q3 		$227K Buy
+1,820
New +$191K 0.02% 148

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCAV
Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
VMV
Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bingham Osborn & Scarborough's TXG Position: Q4 2020 in Review

Bingham Osborn & Scarborough sold out of 10x Genomics (TXG) in Q4 2020, closing a stake of 1,820 shares — an estimated $227K sold.

Bingham Osborn & Scarborough first reported a position in TXG in Q3 2020 and held it in 1 quarter. The position peaked at $227K in Q3 2020. 305 funds tracked by Wall St. Rank hold TXG as of Q4 2020.

  • Bingham Osborn & Scarborough reported no remaining 10x Genomics position as of Q4 2020 after selling out during the quarter.
  • Bingham Osborn & Scarborough sold 1,820 10x Genomics shares in Q4 2020, an estimated $227K.
  • Bingham Osborn & Scarborough first reported a position in 10x Genomics in Q3 2020 and held it in 1 quarter.
  • Bingham Osborn & Scarborough's 10x Genomics position peaked at $227K in Q3 2020.
  • 305 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2020.

Based on Bingham Osborn & Scarborough's 13F filing for Q4 2020, filed 11 Feb 2021.